Detalhe da pesquisa
1.
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.
Am J Hematol
; 97(9): 1170-1177, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35731911
2.
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Lancet Haematol
; 10(11): e890-e901, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37776872
3.
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 40(25): 2901-2912, 2022 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34898239